Abstract
Purpose :
We performed a retrospective clinical study to evaluate growth of polypoidal choroidal vasculopathy(PCV) without exudative findings assessed in En Face optical coherence tomography(OCT) and investigated its clinical importance.
Methods :
Previously diagnosed with PCV in the Pusan national university hospital, patients who had been treated with anti-vascular endothelial growth factor(anti-VEGF) with more than 12 months follow-up from the base point when there was no subretinal fluid collection detected in more than three consecutive visits from Jan. 2009 to June 2015 were included in the retrospective analysis. Patients with a history of photodynamic therapy were excluded, and if there were severe submacular hemorrhage or retinal pigment epithelial tear that complicated accurate macula analysis, those cases were excluded either. Growth of PCV without exudative findings was defined to an increase of neovascular area assessed in En Face OCT in more than three consecutive visits.
Results :
50 eyes of 50 patients were included and the average age was 68.5±8.6. 26 eyes(52.0%, group 1) had growth of PCV without exudative changes in En Face OCT, while 24 eyes(48.0%, group 2) did not show growth. There were no difference in visual acuity and central subfield mean thickness(CSMT) at the base point between group 1 and 2. CSMT was greater in group 1 at 6 and 9 months (229.8±55.2μm / 225.9±55.9μm) than in group 2 (214.3±26.2μm / 219.9±26.3μm) (P=0.027, P=0.001). The average injection number was greater in group 1(3.7±1.7) than group 2(1.8±2.1)(P=0.001). A higher exudative recurrence was noted in 24 eyes(92.3%) of group 1 than 7 eyes(29.2%) of group 2(P<0.001).
Conclusions :
En face OCT was efficient in evaluating abnormal vascular growths without exudative findings in PCV patients. Vascular growth without exudative changes proved to be a factor that predicts exudative recurrence.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.